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Abstract:  Globally, over 170 million people (ca. 3% of the World’s population) are 
infected with the hepatitis C virus (HCV), which can cause serious liver diseases such as 
chronic hepatitis, evolving into subsequent health problems. Driven by the need to detect 
the presence of HCV, as an essential factor in diagnostic medicine, the monitoring of viral 
protein has been of great interest in developing simple and reliable HCV detection 
methods. Despite considerable advances in viral protein detection as an HCV disease 
marker, the current enzyme linked immunosorbent assay (ELISA) based detection methods 
using antibody treatment have several drawbacks. To overcome this bottleneck, an RNA 
aptamer become to be emerged as an antibody substitute in the application of biosensor for 
detection of viral protein. In this study, we demonstrated a streptavidin-biotin conjugation 
method, namely, the RNA aptamer sensor system that can quantify viral protein with 
detection level of 700 pg mL
−1 using a biotinylated RNA oligonucleotide on an Octet 
optical biosensor. Also, we showed this method can be used to screen inhibitors of viral 
protein rapidly and simply on a biotinylated RNA oligonucleotide biosensor. Among the 
inhibitors screened, (−)-Epigallocatechin gallate showed high binding inhibition effect on 
HCV NS5B viral protein. The proposed method can be considered a real-time monitoring 
method for inhibitor screening of HCV viral protein and is expected to be applicable to 
other types of diseases. 
OPEN ACCESSSensors 2011, 11  
 
 
6686
Keywords: viral protein; streptavidin-biotin conjugation; RNA oligonucleotide; inhibitor 
 
1. Introduction  
Hepatitis C virus (HCV) is of great interest as a worldwide infectious disease that can result in acute 
and chronic hepatitis, cirrhosis, and the development of hepatocellular carcinoma. Globally, 
approximately 3% of the world’s population or more than 170 million people are infected. HCV 
infection causes serious liver diseases such as chronic hepatitis, which can evolve into subsequent 
more serious health problems [1-4]. HCV RNA replication was catalyzed using viral polymerase 
nonstructural protein 5B (NS5B). This RNA-dependent RNA polymerase synthesizes a negative-strand 
RNA that serves as a template for the synthesis of new positive RNA strands. As a crucial and unique 
component of its viral replication machinery, the RNA-dependent polymerase of HCV plays a pivotal 
role in its life cycle [5-7]. Due to its essential role in viral replication, HCV NS5B viral protein has 
been mainly regarded as a prime target for antiviral therapy. For this reason, HCV NS5B is an 
attractive and crucial target for anti-HCV therapeutic drug discovery. Recently, the most widely 
analyzed method of diagnosing HCV is the detection of anti-HCV antibodies using a screening 
enzyme-linked immunosorbent assay (ELISA) based on recombinant proteins from the HCV   
genome [8]. While it is highly sensitive and specific, this assay has certain limitations [9]. For 
example, it cannot detect viruses during an early stage of infection, at a time when antibodies against 
HCV antigens are not yet being produced. In addition, the ELISA method sometimes generates   
false-positive or false-negative results. As another method of HCV diagnosis, the reverse transcriptase 
(RT)-polymerase chain reaction (PCR) method has been shown to amplify and detect HCV [10]. 
However, the RT-PCR method is labor-intensive, expensive, and prone to contamination. Also, the 
time required to perform a PCR limits its clinical application. Driven by the need to design novel 
approach for detection, an accurate and sensitive diagnosis of HCV diseases is crucial and essential. To 
overcome these bottlenecks, aptamers are introduced as an antibody and RT-PCR substitute in the 
application of biosensors for the detection and monitoring of biomolecules [11-14]. Aptamers are 
single-stranded nucleic acids that detect high affinity binding to various targets, small molecule, 
glycan, peptide, protein and biomolecules [15,16]. Recently, nucleic acid-based aptamers have been 
developed for a variety of diagnostic applications, including the detection of wide nucleic acid   
analytes [17]. The Octet optical biosensor platform was recently reported to be an instrument for 
higher-throughput, label-free, real-time molecular interaction analysis [18]. 
There is a need for a feasible method to detects the presence of an HCV infection, such as a direct 
RNA-based HCV viral protein detection method. Driven by the need to detect the presence of the HCV 
diseases, in this study, we demonstrate for the first time that biotinylated RNA oligonucleotide with a 
functional signal sequence can be used for screening and quantifying HCV RNA with selectivity and 
specificity. We also show that biotin-tagged RNA oligonucleotide can be used as a probe for the 
detection HCV viral protein NS5B and inhibitor screening on forteBio’s Octet optical biosensor 
system. The goal of this study is to investigate direct HCV viral protein detection and rapid inhibitor Sensors 2011, 11  
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screening with a specific biotinylated RNA oligonucleotide using a streptavidin-biotin conjugation 
method on forteBio’s Octet optical biosensor system.  
2. Experimental Section 
2.1. Chemicals and RNA Oligonucleotide  
(−)-Epigallocatechin gallate and cyclosporin A were purchased from Sigma-Aldrich Chemical Co. 
(St. Louis, MO, USA). The biotinylated group with terminal modification of NS5B RNA 
oligonucleotide was synthesized by BIONEER Co. Ltd. (Seoul, Republic of Korea). The biotinylated 
sequences of NS5B RNA oligonucleotide (NS5B: 5’-ggccacauugugaggggcuc-3’-biotin) were used as a 
specific probe. All other chemicals were of the highest grade. 
2.2. Subcloning, Expression and Purification of HCV Viral Protein  
The HCV NS5B gene, except for the hydrophobic C terminus 21 amino acids, was amplified using 
polymerase chain reaction (PCR) with a primer set, sense (5’-cgcgaattcatgtcctacacatggacagg-3’) and 
antisense (5’-tttctcgagtcggttggggagcaggta-3’), containing restriction enzyme sites of EcoRI/XhoI. The 
PCR product was digested using EcoRI/XhoI, and then ligated into EcoRI/XhoI digested expression 
vector pET 28a
+ (Novagen, Madison, WI, USA), and transformed into E. coli DH5 α (Stratagene,  
La Jolla, CA, USA). The transformant was grown in a 250 mL flask containing a 50 mL Luria-Bertani 
(LB) medium supplemented with 50 µg mL
−1 of kanamycin at 37 °C until the cell concentration 
reached an OD600nm of 0.6, and isopropylthio-β-D-galactopyranoside (IPTG) to a final concentration 
of 0.1 mmol L
−1, followed by additional growth overnight at 25 °C while shaking at 180 rpm. The 
harvested cells were lysed using a Sonicator (W250 Sonifier, Branson, Dietzenbach, Germany). The 
supernatant was collected and the recombinant viral protein was purified using a Ni-nitrilotriacetic acid 
(Ni-NTA) affinity chromatography column (Qiagen, Germany). The supernatant was equilibrated with 
buffer A (10 mmol L
−1 Tri-HCl, 500 mmol L
−1 NaCl, 20 mmol L
−1 imidazole, 2 mmol L
−1 EDTA,  
1 mmol L
−1 PMSF, pH 8.0). The bound protein was then eluted with buffer B (10 mmol L
−1 Tris-HCl, 
500 mmol L
−1 NaCl, 500 mmol L
−1 imidazole, 2 mmol L
−1 EDTA, 1 mmol L
−1 PMSF, pH 8.0) at 4 °C. 
The purity of the purified protein was estimated using SDS-PAGE in the eluted fractions, using 10% 
polyacrylamide running gels [19]. The HCV NS5B viral protein was purified using a single 
chromatography step on a Ni
2+ affinity column. The protein concentration was determined as described 
by Bradford with a bovine serum albumin (BSA) as standard [20].  
2.3. Detection of Viral Protein NS5B and Screening of Inhibitor on Octet Platform  
For the study, Octet QK, equipped with streptavidin (FA) biosensor tips, was purchased from 
forteBio (Menlo Park, CA, USA). Streptavidin-coated FA tips were saturated with 0.1 μg mL
−1 
biotinylated RNA oligonucleotide (15 min). The typical capture levels were 2.65 ± 0.32 nm with the 
standard deviation being within the instrument noise. A 10 min washing step was added. To study the 
interactions with biotinylated RNA oligonucleotide on the tip, a viral protein was also prepared as a 
five-member tenfold serial dilution with a highest concentration of 7 × 10
0 μg mL
−1 by 7 × 10
−4 μg mL
−1. 
Then, a viral protein of 7 × 10
0 μg mL
−1 to 7 × 10
−4 μg mL
−1 was bound to the biotinylated RNA Sensors 2011, 11  
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oligonucleotide for 10 min and allowed to dissociate into a buffer (10 mmol L
−1 potassium phosphate, 
2 mmol L
−1 EDTA, and 1 mmol L
−1 PMSF at pH 7.4) for 10 min. Blank binding cycles containing no 
RNA oligonucleotide were used to correct for the baseline drift. Temperature control of the Octet was 
accomplished by keeping the instrument in a 22 °C temperature-controlled room so that it could be 
heated to 25 °C. Sensor tips were pre-wetted for 2 min in a buffer immediately prior to use, and the 96 
well microplate used in the Octet was filled with 200 μL of the sample or buffer per well and agitated 
at 1,000 rpm. For the inhibition activity, the RNA oligonucleotide and inhibitor were facilitated 
through by adding on an Octet platform. The value of the signal intensity was obtained by calculating 
and expressing it as the mean intensity. 
3. Results and Discussion 
3.1. Scheme for HCV Viral Protein NS5B Detection on Octet Optical Biosensor 
Specific detection of a viral protein was demonstrated using a biotinylated RNA oligonucleotide via 
the streptavidin-biotin conjugation method, which makes a simple analysis of RNA-protein 
interactions possible. The design of a sensor for effective detection of HCV viral protein using the 
streptavidin-biotin conjugation method is illustrated in Figure 1. The complete procedure for the 
detection of viral protein NS5B using the streptavidin-biotin conjugation method is as follows. First, a 
biotinylated RNA oligonucleotide is conjugated using a streptavidin sensor on a tip. Second, the 
streptavidin-biotin conjugated RNA oligonucleotide is washed to remove unspecific binding. Third, 
the viral protein is bound to streptavidin-biotin conjugated RNA oligonucleotide as association phase. 
Fourth, as dissociation phase, the biotinylated RNA oligonucleotide is analyzed in order to identify the 
specific detection of viral protein in the streptavidin-biotin conjugation method. To accomplish the 
feasibility of the targeting and monitoring, biotinylated RNA oligonucleotide conjugates having 
specific affinity capacity for detection of viral protein NS5B were used. Bovine serum albumin (BSA) 
as a reference protein was analyzed.  
Figure 1. A representative scheme for detection of viral protein using streptavidin-biotin 
conjugation method on the Octet platform. 
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3.2. Principle of Octet Platform  
Detection technology of BioLayer Interferometry (BLI) invented by Lotze [21] is a label-free, 
fluidics-free, real-time detection based on an optically-coated Streptavidin biosensor [22]. 
Interferometry is a technique based on the measurement of light intensity produced by an interference 
of two or more light beams. This technique can be used for detecting optical properties, such as a 
refraction index, and physical properties, such as the thickness of a thin film when a difference 
between the light beams is due to the light passing through it. The principle of the Octet optical 
biosensor for detection technology in the BLI method is illustrated in Figure 2.  
Figure 2. Proprietary new technology for label-free detection. A layer of molecules 
attached to the tip of an optic fiber creates an interference pattern at the detector with 
optically coated streptavidin biosensor in solution. Any change in the number of molecules 
bound causes a measured shift in the pattern, Biolayer Interferometry (BLI) surface 
chemistry. Relationship of distance between reflecting surfaces and reflected intensity 
would be investigated. As molecules bind, the spectrum of signal changes as a function of 
the layer increasing on the sensor. 
 
 
In Figure 2, the biotinylated RNA oligonucleotide is attached to a tip coated with a streptavidin 
optical layer. The tip is dipped into a sample containing the target molecule. The target molecule binds 
to the captured molecule, and the two form a molecular layer. A white light is directed into the fiber. 
Two beams will be reflected to the back end. The first beam comes from the tip as a reference. The 
second light comes from the molecular layer. The difference in the two beams will cause a spectrum 
color pattern as shown here. The phase is a function of the molecular layer thickness and corresponds 
to the number of molecules on the tip surface. When the molecules bind to the sensor, the reflections 
on the internal reference layer will remain constant, while those on the interface between the molecular 
layer on the fiber and the solution will change with the addition of bound molecules. Bio-layer 
interferometry within our sensor will monitor this change. For a thin film based on an optically-coated Sensors 2011, 11  
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streptavidin biosensor placed on a molecule, that is, the biotinylated RNA oligonucleotide, the two 
interfering beams in reflection mode can be as follows: first, a beam passing through the thin film and 
reflected from the interface between the substrate and the film; or alternatively, a beam reflecting from 
the interface between the thin film and the air. If the biotinylated RNA oligonucleotide is optically 
transparent, interference can also be measured in transmission mode. Interferometry can be used for 
detecting a change in thickness of an organic film, comprised of an RNA-protein molecules binding, 
consequent to exposure to a biological sample, and thereby determining the amount of RNA-protein 
conjugates in the sample by detecting change in thickness. Bio-layer interferometry within an   
Octet sensor will detect and monitor this change in real-time detection technology based on an   
optically-coated streptavidin biosensor. As RNA oligonucleotide binds to viral protein NS5B, the 
spectrum of the signal will change as a function of the signal increasing on the sensor. The Octet will 
monitor changes in wavelength over time. This real-time binding measurement can be used to calculate 
the on and off rates (Equation 1), and ultimately the concentration by plotting rates against 
concentration: 
kd = koff/kon        ( 1 )  
We demonstrated the specific interaction between biotinylated RNA oligonucleotide and HCV viral 
protein on forteBio’s Octet platform, which uses biolayer interferometry to detect and quantify 
molecular interactions using disposable streptavidin biosensor that addresses biotinylated RNA 
oligonucleotide and viral protein interactions from open shaking 96 well microplates without a labeling 
procedure. An assay for the biotinylated RNA oligonucleotide conjugation was created on a 
streptavidin sensor. Streptavidin-coated FA tips were saturated with 0.1 μg mL
−1 biotinylated NS5B 
RNA oligonucleotide for 900 s. The washing step allowed the removal of unspecific binding of 
biotinylated RNA oligonucleotide. The viral protein NS5B was prepared with a serial dilution of   
7 × 10
0 μg mL
−1 to 7 × 10
−4 μg mL
−1 to study the interactions with biotinylated RNA oligonucleotide 
on the streptavidin sensor tip. The samples were allowed to associate for 900 s. Dissociation was 
measured for 600 s.  
3.3. Expression and Purification of Viral Protein NS5B 
In Figure 3, the recombinant HCV NS5B viral protein in an E. coli expression system was expressed 
and purified using Ni-NTA affinity chromatography. In the purification step, the protein was eluted in 
a 1 mL fraction with a 250 mmol L
−1 imidazole buffer. To verify the purity and homogeneity of the 
eluted NS5B, aliquots of eluted fractions were analyzed using Coomassie blue staining on SDS-PAGE. 
Eluates with the highest purity of 95% were pooled, dialyzed and stored with 50% glycerol in aliquots 
at −80 °C. The HCV NS5B viral protein was purified using a single chromatography step on a Ni
2+ 
affinity column. The C-terminally his-tagged HCV NS5B was purified with a molecular mass of 
approximately 66 kDa. 
3.4. Biosensor Effect of RNA Oligonucleotide on Viral Protein 
As illustrated in Figure 4(A), the biotinylated RNA oligonucleotide showed high binding affinity 
signals on the streptavidin (FA) biosensor. Furthermore, Figure 4(A) shows that conjugated RNA Sensors 2011, 11  
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oligonucleotide is selective for HCV NS5B viral protein at increasing protein concentrations. The 
binding affinity from the Octet biosensor assay with varying concentrations of the NS5B viral protein 
was examined, and it was observed that the signal intensity of the conjugated RNA oligonucleotide 
could be detected even at the lowest concentration of 700 pg mL
−1. The signal intensity was found to 
increase gradually by up to 7 μg mL
−1 of protein concentration. Figure 4A shows that the detection 
limit of this method was at the 700 pg mL
−1 level. These results suggest the NS5B RNA 
oligonucleotide can specifically target the HCV NS5B viral protein on an Octet platform. The reason 
of this result will be postulated RNA oligonucleotide (5'-ggccacauugugaggggcuc-3') used as a specific 
probe may interact to the active site of HCV NS5B viral protein. These results show that biotinylated 
RNA oligonucleotide can be effective for the quantification of HCV NS5B viral protein. In Table 1, 
the method and limitation for the detection of HCV viral protein were compared. The detection level of 
viral protein NS5B by a conventional method such as ELISA was approximately 2 ng mL
−1 [23].  
As another method, the QDs-based RNA aptamer sensor system showed a lower detection limit of  
1 ng mL
−1 for the evaluation of HCV viral protein NS5B [24]. The Octet biosensor assay using a 
streptavidin-biotin conjugation method showed the lowest detection limit of 700 pg mL
−1. This result 
suggests that the biotinylated RNA oligonucleotide could specifically target the HCV NS5B protein in 
an Octet biosensor system.  
Figure 3. Purification of HCV NS5B viral protein. It represents the SDS-PAGE 10% gel 
showing NS5B protein with his-tag. M, protein marker; lane 1, before induction lysate; 
lane 2, total lysate; lane 3, soluble lysate; lane 4, his-tag form of purified HCV NS5B. 
 
In Figure 4(B), the preferential binding affinity of conjugated RNA oligonucleotide for detection of 
HCV NS5B viral protein was determined by analyzing the binding signal intensity measured on an 
Octet platform. Figure 4(B) shows that the binding affinity value was 6.3 nM. To confirm the 
competition reaction of specific binding, BSA was used as a negative reference. No binding affinity 
signal was detected with BSA because of its lack of affinity (data not shown). The signal of NS5B 
RNA oligonucleotide for BSA binding affinity was very similar to the background signal. Using the 
Octet biosensor system, we have developed a HCV detection method that can detect and quantify viral Sensors 2011, 11  
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protein in solution. Here, the specific RNA oligonucleotide was examined for binding to the HCV 
NS5B viral protein by using a streptavidin-biotin conjugated method. It could be concluded that the 
detection and monitoring of viral protein by the Octet biosensor system is convenient and efficient 
with high specificity and sensitivity.  
Figure 4. (A) Using the Octet interferometer (forteBio), the following assay was 
developed to monitor the specificity of RNA binding protein, high affinity HCV NS5B and 
specific RNA oligonucleotide; (B) Binding affinity value on streptavidin-biotin 
conjugation for real-time monitoring (kd value). 
 
Table 1. The method and limitation for detection of HCV viral protein. 
Source Method  Probe  Detection  limit  Reference 
NS5B  ELISA  antibody  2 ng mL
−1 22 
NS5B Biochip 
QD-based RNA 
Oligonucleotide 
1 ng mL
−1 23 
NS5B 
Octet 
biosensor 
biotinylated RNA 
Oligonucleotide 
700 pg mL
−1  In this study Sensors 2011, 11  
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3.5. Inhibitory Effect of Viral Protein NS5B 
In Table 2, the effects of flavonoid compounds and cyclosporin A on the inhibition of the viral 
protein NS5B used in this study are presented. Many researchers have reported that cyclosporin A is 
one of the most remarkable drugs for viral protein NS5B. To evaluate the effects of cyclosporin A on 
viral protein NS5B, we used it as a known NS5B inhibitor for elucidation of our designed biochip 
platform [25]. We confirmed cyclosporine A concentration-dependent binding inhibition activity 
against viral protein NS5B [Figure 5(A)]. Among molecules screened, (−)-epigallocatechin gallate 
showed high binding inhibition activity [Figure 5(B)].There was no inhibition activity in flavonoids, 
isoflavonoids and (−)-catechin. Ivanov and Kozlov reported the inhibitory effect of 
trihydroxybenzaldehyde (gallic aldehyde) on NS5B protein activity [26,27]. Epigallocatechin   
3-gallate, effective inhibitor such as pyrogallol derivatives was found. We demonstrated inhibitor 
screening on a designed Octet biosensor platform using a RNA oligonucleotide. We discovered a novel 
function of (−)-Epigallocatechin gallate as a binding inhibition agent on HCV NS5B viral protein. The 
discovery of a binding inhibition agent on HCV NS5B viral protein has been of considerable interest in 
developing efficient and effective methods for high-throughput screening in medicine. 
Table 2. The effects of flavonoid compounds and cyclosporine A on the binding inhibition 
of viral protein NS5B used in this study. 
Compounds Inhibition  Effect 
Naringenin  − 
Hesperetin  − 
Apigenin  − 
Luteolin  − 
Quercetin  − 
Rutin  − 
Fisetin  − 
Myricetin  − 
(−)-Catechin  − 
(−)-Epigallocatechin 3-gallate  + 
Biochanin A  − 
Formononetin  − 
Daidzein  − 
Genistein  − 
Glycitein  − 
Cyclosporin A  + 
      +: It means this compound has inhibition activity on viral protein NS5B. 
   −: It means this compound has no inhibition activity on viral protein NS5B. 
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Figure 5. Inhibitory effect of (A) cyclosporin A and (B) (−)-epigallocatechin gallate on 
viral protein NS5B. 
 
4. Conclusions 
In summary, we demonstrated a RNA aptamer system that can effectively detect and monitor HCV 
viral protein using biotin-based RNA oligonucleotide on an Octet platform. The monitoring of HCV 
viral protein has been of considerable interest in developing simple and reliable methods for HCV 
detection in diagnostic medicine applications. Our main goal in this study is to demonstrate the   
proof-of-concept that viral protein can be detected and monitored with remarkable selectivity and 
specificity. For application, this designed platform for a novel inhibitor assay possesses significant 
potential as a target screening. As these results show, RNA-protein interactions may be of great utility 
in the identification of novel RNA binding proteins and in understanding how proteins recognize 
particular RNA sequences. An RNA oligonucleotide biosensor based on the streptavidin-biotin 
conjugation method has attracted significant attention and has become a promising method for the 
specific detection of oligonucleotide because of its high sensitivity, low cost, rapid response, and low 
labor-intensive requirements. The proposed method can be considered an efficient strategy and new 
promising platform for monitoring applications. 
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